Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610119 | 0.84 | ALDH1A1 (0.44) | ALDH1A1GGPS1MAPTCYP2C9CYP2C19 | |
| SCHEMBL18177969 | 0.81 | CYP2C9 (0.39) | ALDH1A1MAPTCYP2C9CYP2C19 | |
| SCHEMBL1563400 | 0.78 | NR1I2 (0.51) | ALDH1A1MEN1GAAMAPTKMT2A | |
| SCHEMBL4611213 | 0.77 | TSHR (0.55) | MAOBALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL4611045 | 0.77 | CES1 (0.41) | HTTSMN1; SMN2ALDH1A1MEN1S1PR2 | |
| SCHEMBL4612087 | 0.74 | CYP3A4 (0.42) | SMN1; SMN2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL17169186 | 0.73 | ALDH1A1 (0.61) | HTTSMN1; SMN2ALDH1A1GGPS1CYP2C9 | |
| Phenyl Diphenoxyphosphinecarboxylate Oxide SCHEMBL4610556 | 0.73 | SRC (0.54) | MAPTCYP2C9CYP2C19 | |
| SCHEMBL4610697 | 0.73 | FAAH (0.47) | — | |
| SCHEMBL24072545 | 0.73 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2ALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10374256-B2 | Nonaqueous electrolyte solution, electricity storage device using same, and phosphonoformic acid compound used in same | UBE INDUSTRIES, LTD. (JP) | 2019-08-06 | — | — | US | disclosed |
| US-20160315351-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME | UBE INDUSTRIES, LTD (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-1419182-B1 | IRON-BASED CATALYST COMPOSITION FOR THE MANUFACTURE OF SYNDIOTACTIC 1,2-POLYBUTADIENE | BRIDGESTONE CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1419182-A1 | IRON-BASED CATALYST COMPOSITION FOR THE MANUFACTURE OF SYNDIOTACTIC 1,2-POLYBUTADIENE | Bridgestone Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6610804-B2 | An iron compound, an alpha-acylphosphonate diester, and an organoaluminum compound | BRIDGESTONE CORPORATION (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6576725-B1 | Iron compound, organomagnesium compound, and alpha-acylphosphonate diester; addition polymerization | BRIDGESTONE CORPORATION (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20030073570-A1 | Method of preparing oligomers of conjugated dienes with an iron-based catalyst composition | BRIDGESTONE CORP. | 2003-04-17 | — | — | US | disclosed |
| US-20030073790-A1 | Iron-based catalyst composition for the manufacture of syndiotactic 1, 2-polybutadiene | BRIDGESTONE CORP. | 2003-04-17 | — | — | US | disclosed |
| WO-2003018644-A1 | IRON-BASED CATALYST COMPOSITION FOR THE MANUFACTURE OF SYNDIOTACTIC 1,2-POLYBUTADIENE | BRIDGESTONE CORPORATION (JP) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10374256-B2 | Nonaqueous electrolyte solution, electricity storage device using same, and phosphonoformic acid compound used in same | HCN2, PHOSPHO1, HCN1 | HTT 3372/4885MAOB 4162/4885SMN1; SMN2 1393/4885 |
| US-20160315351-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME | HCN2, PHOSPHO1, HCN1 | HTT 3372/4885MAOB 4162/4885SMN1; SMN2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.